These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33009692)

  • 21. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma.
    Yao Y; Yan Z; Lian S; Wei L; Zhou C; Feng D; Zhang Y; Yang J; Li M; Chen Y
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32719094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
    Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients.
    Chen B; Han Y; Sheng S; Deng J; Vasquez E; Yau V; Meng M; Sun C; Wang T; Wang Y; Sheng M; Wu T; Wang X; Liu Y; Lin N; Zhang L; Shao W
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):91. PubMed ID: 38347320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas.
    Ma B; Li H; Qiao J; Meng T; Yu R
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance.
    Han Y; Shi Y; Chen B; Wang J; Liu Y; Sheng S; Fu Z; Shen C; Wang X; Yin S; Li H
    Front Immunol; 2022; 13():961695. PubMed ID: 36389709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.
    Chen Y; Nie J; Li X; Fan T; Deng X; Liang D; Song G
    J Immunol Res; 2021; 2021():6661625. PubMed ID: 33506058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
    Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
    Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
    Li J; Tang LL; Ma J
    BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Shi Y; Huang J; Hu Y; Shen Y
    BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
    Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
    Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ferroptosis-associated DNA methylation signature predicts overall survival in patients with head and neck squamous cell carcinoma.
    Xu Y; Hong M; Kong D; Deng J; Zhong Z; Liang J
    BMC Genomics; 2022 Jan; 23(1):63. PubMed ID: 35042463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel CAF-cancer cell crosstalk-related gene prognostic index based on machine learning: prognostic significance and prediction of therapeutic response in head and neck squamous cell carcinoma.
    Xu Y; Li J; Wang J; Deng F
    J Transl Med; 2024 Jul; 22(1):645. PubMed ID: 38982511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma.
    Du K; Zou J; Wang B; Liu C; Khan M; Xie T; Huang X; Shen P; Tian Y; Yuan Y
    Front Immunol; 2022; 13():857934. PubMed ID: 35844514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration.
    Liu Z; Zhang D; Liu C; Li G; Chen H; Ling H; Zhang F; Huang D; Wang X; Liu Y; Zhang X
    Front Immunol; 2021; 12():659184. PubMed ID: 33995379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
    Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
    World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma.
    Xu X; Pan X; Fan Z; Xia J; Ren X
    Cell Signal; 2024 Aug; 120():111200. PubMed ID: 38719019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of two distinct head and neck squamous cell carcinoma subtypes based on fatty acid metabolism-related signatures: Implications for immunotherapy and chemotherapy.
    Zou J; Dai Y; Xu G; Kai Y; Lan L; Zhang J; Wang Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37824. PubMed ID: 38640298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.